Georges Gemayel
CIK 1256088 · Executive Chair of the Board · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GENZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BEDMINSTER, NJ 07921
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Director | — | $79.46 | — | $0 | 5 | 2026-06-23 |
| SUPN | Director | 28,159 | $41.55 | $1.17M | -$2.35M | 22 | 2026-03-09 |
| Disc Medicine, Inc. (GMTX) Delisted | Executive Chair of the Board | — | $13.50 | — | $0 | 3 | 2022-01-05 |
| MOMENTA PHARMACEUTICALS INC (MNTA) Delisted | Director | 0 | — | — | -$630.0K | 8 | 2020-10-01 |
| Dimension Therapeutics, Inc. (DMTX) Delisted | Director | — | — | — | $0 | 3 | 2017-11-07 |
| Raptor Pharmaceutical Corp (RPTP) Delisted | Director | 0 | — | — | $0 | 4 | 2016-10-26 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | Director | 0 | — | — | -$233.3K | 9 | 2015-02-24 |
| RPRX | Director | 1,852 | $61.79 | $114.4K | $0 | 5 | 2010-05-19 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | President & CEO | — | $10.12 | — | $0 | 4 | 2009-02-23 |
| GENZ | Executive Vice President | 14,090 | $38.48 | $542.2K | -$2.85M | 3 | 2007-11-02 |
Recent Filings · Page 2 of 8
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-11-12 | SUPN | Mixed | — | -$267.9K | EDGAR |
| 2024-11-08 | SUPN | Notice (144) | −10,787 | -$391.5K | EDGAR |
| 2024-11-08 | SUPN | Mixed | — | -$357.6K | EDGAR |
| 2024-11-07 | SUPN | Notice (144) | −14,213 | -$520.5K | EDGAR |
| 2024-09-17 | SUPN | Mixed | −3,886 | -$320.4K | EDGAR |
| 2024-09-13 | SUPN | Notice (144) | −13,886 | -$435.0K | EDGAR |
| 2024-06-14 | IRON | Grant (A) | — | $0 | EDGAR |
| 2024-02-27 | SUPN | Mixed | +3,886 | $0 | EDGAR |
| 2024-02-26 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | IRON | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.